Today: 29 April 2026
Browse Category

NASDAQ:ADAP 19 August 2025 - 16 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune shares jumped 52% on October 8, 2025, amid heavy speculative trading, but remain down about 75% year-over-year and trade near $0.20. The company sold its main T-cell therapy programs to US WorldMeds for $55 million upfront, cleared its debt, and now faces “substantial doubt” about its ability to continue. Analysts rate the stock as high risk, with no major firm recommending a Buy.
9 October 2025
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics shares soared 42% to around $0.20 on Oct. 8, 2025, after weeks of extreme volatility and trading volumes topping 705 million shares. The company sold its four main cell therapy programs, including newly approved Tecelra, for $55 million upfront in July to pay off debt and cut its workforce by 62%. Weiss Ratings issued a rare “Sell (E+)” on Oct. 8. No new products have been announced this month.
8 October 2025
·
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····

Stock Market Today

  • US Stocks Slip as Oil Prices Surge, Tech Shares Weigh on Market
    April 29, 2026, 10:27 AM EDT. US stocks edged lower with the S&P 500 down 0.2%, retreating after recent all-time highs. The Dow Jones fell 97 points, also 0.2%, while the Nasdaq Composite declined 0.4%. Artificial intelligence stocks led the losses amid growing concerns over surging oil prices, which are adding pressure on market sentiment. Investors remain cautious as higher energy costs raise fears over inflation and corporate earnings. The pullback signals a pause following tech-driven gains, highlighting how energy price volatility continues to influence trading dynamics.

Latest article

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

29 April 2026
Enphase Energy shares dropped 7.3% to $31.80 after reporting a first-quarter revenue decline to $282.9 million and a GAAP loss of $7.4 million. U.S. revenue fell 23% from the prior quarter, with sell-through demand down 48% sequentially. Adjusted earnings beat estimates, but investors appeared unconvinced demand had stabilized. SolarEdge and Sunrun shares also fell in early trading.
Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

29 April 2026
Western Digital shares rose 9.3% to $427.45 Wednesday after Seagate’s quarterly forecast topped estimates and sent storage stocks higher. Seagate shares jumped 16.6%. Seagate projected fourth-quarter revenue of $3.45 billion and non-GAAP earnings of $5 a share. Western Digital will report fiscal third-quarter results after markets close Thursday.
Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

29 April 2026
Generac Holdings raised its 2026 sales outlook after first-quarter net sales rose 12% and commercial and industrial sales jumped 28% to $510 million, driven by data center demand. Shares climbed 11% after adjusted earnings of $1.80 a share beat estimates. The company now expects full-year net sales growth in the mid-to-high teens percentage range, up from its prior forecast. Generac also increased its adjusted EBITDA margin guidance.
Go toTop